Company Profile:

 

§Advanced Plant Pharmaceuticals, Inc., (APPI) is the innovator of whole plant pharmaceuticals and is a pharmaceutical company dedicated to utilizing whole plants to develop products for the treatment of human diseases. APPI has developed and protected a unique method of manufacturing such products without extracting active ingredients. This unique manufacturing process, enabled the Company to receive the first patent and IND (investigational new drug) on a whole plant pharmaceutical. APPI takes pride in itself as being the innovator of whole plant technology.

§

§

The Company's roots began in 1987, as a research program to study the use of whole plants as a source of pharmaceutical products to enhance the immune system to combat debilitating diseases, such as HIV and AIDS. The founders believed that whole plants would provide a safer, and less expensive product than chemical based compounds.

§

§

The Company went Public in 1994 through a reverse merger with Ventra Management, a publicly-traded company which was renamed Advanced Plant Pharmaceuticals Inc. to reflect the change in operations.

§

APPI received its first formulation patent on their Cholesterol lowering agent, "Lo-Chol", a whole plant product derived from six different botanicals. Patients in clinical studies have shown that the botanicals used in this formulation help lower total Cholesterol 20%, lower triglycerides 45%, and also increase HDL 60% and the proportion of HDL (the good Cholesterol) to LDL (bad Cholesterol).

§

§The cholestrol market in the USA is valued at over $17B per year and APPI has hired Ed McMahon as a International spokesperson for a national and international marketing campaign.

§

§

In addition to the Lo-Chol patent, the Company also has submitted patents on their processing methods, Leuknil, a whole plant product to be utilized for the treatment of Leukemia and cancer, and LMH-123 for the treatment of Alzheimers disease.

§

§

APPI also owns Sinusol, which is an Allergy Sinus Solution (AS2760) - it is a generalized base solution for the development of an extensive line of specialty products related to allergy and sinus conditions. This should combat various symptoms related to allergies and sinus disorders and include congestions, irritated nasal mucosa, and bacterial and fungal infections.   The allergy-sinus market is valued at over $3B per year

For further information please email IR@advancedplantpharm.com or call by phone (212) 695-3334.